Therapeutic modulation of mitochondrial dynamics by agmatine in neurodegenerative disorders
- 29 January 2025
- journal article
- review article
- Published by Elsevier in Neuroscience
- Vol. 569, 43-57
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology, India
- Anusandhan National Research Foundation (EEQ/ 2021/000955)
This publication has 187 references indexed in Scilit:
- The role of mitochondrial dysfunction in Alzheimer's disease pathogenesisAlzheimer's & Dementia, 2022
- Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic reviewJournal of Neurology, 2021
- Arginine depriving enzymes: applications as emerging therapeutics in cancer treatmentCancer Chemotherapy and Pharmacology, 2021
- Arginine, Agmatine, and Polyamines: Key Regulators of Conceptus Development in Mammals2021
- Nitrogen‐containing flavonoid and their analogs with diverse B‐ring in acetylcholinesterase and butyrylcholinesterase inhibitionDrug Development Research, 2020
- Structure–activity study of fluorine or chlorine‐substituted cinnamic acid derivatives with tertiary amine side chain in acetylcholinesterase and butyrylcholinesterase inhibitionDrug Development Research, 2019
- Mitochondrial Dysfunction in Huntington’s Disease2018
- The genetic architecture of mitochondrial dysfunction in Parkinson’s diseaseCell and tissue research, 2018
- Mitochondrial DNA damage and reactive oxygen species in neurodegenerative diseaseFEBS Letters, 2017
- Agmatine protects rat liver from nicotine-induced hepatic damage via antioxidative, antiapoptotic, and antifibrotic pathwaysNaunyn-Schmiedeberg's Archives of Pharmacology, 2016